Compositions and methods for viral sensitization
US-2024360115-A1 · Oct 31, 2024 · US
Compositions and methods for enhancing virus replication
US10066214B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10066214-B2 |
| Application number | US-201414898083-A |
| Country | US |
| Kind code | B2 |
| Filing date | Jun 16, 2014 |
| Priority date | Jun 14, 2013 |
| Publication date | Sep 4, 2018 |
| Grant date | Sep 4, 2018 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
First claim
Opening claim text (preview).
What is claimed is: 1. An isolated oncolytic virus particle having a genome comprising an open reading frame that encodes FGF2 protein or a functional variant thereof, and an open reading frame that encodes a Type 1 interferon scavenger. 2. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence selected from SEQ ID NOs: 2-13. 3. The isolated oncolytic virus particle according to claim 1 , wherein the Type 1 interferon scavenger is B18R protein. 4. The isolated oncolytic virus particle according to claim 3 , wherein the B18R protein comprises an amino acid sequence according to SEQ ID NO: 15, 16 or 17. 5. The isolated oncolytic virus particle according to claim 1 , wherein the oncolytic virus is a rhabdovirus, a vaccinia virus, or a herpes simplex virus-1. 6. The isolated oncolytic virus particle according to claim 5 wherein the rhabdovirus is vesicular stomatitis virus, VSVΔ51, VSV IFN-β, maraba virus, or MG1 virus. 7. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 13. 8. The isolated oncolytic virus particle according to claim 1 , wherein the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 2. 9. The isolated oncolytic virus particle according to claim 3 , wherein the B18R protein comprises an amino acid sequence according to SEQ ID NO: 15. 10. The isolated oncolytic virus particle according to claim 1 , wherein: the FGF2 protein comprises an amino acid sequence according to SEQ ID NO: 2; the genome further comprises an open reading frame that encodes a B18R protein that comprises an amino acid sequence according to SEQ ID NO: 15; and the oncolytic virus is a rhabdovirus virus. 11. The isolated oncolytic virus particle according to claim 10 , wherein the rhabdovirus is MG1 virus. 12. The isolated oncolytic virus particle according to claim 10 , wherein the rhabdovirus is vesicular stomatitis virus.
Assignees
Inventors
Classifications
Antineoplastic agents · CPC title
Methods of production or purification of viral material · CPC title
for cytokines; for lymphokines; for interferons · CPC title
Methods of production or purification of viral material · CPC title
Methods of production or purification of viral material · CPC title
Patent family
Related publications grouped by family.
External sources
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US10066214B2 cover?
- Described herein is a method of enhancing virus replication in permissive cells that express a receptor to FGF2 protein. The method includes administering FGF2 protein or a functional variant thereof and the virus to the permissive cells. An oncolytic virus having a genome that includes an open reading frame that encodes FGF2 protein or a functional variant thereof is also described.
- Who is the assignee on this patent?
- Ottawa Hospital Res Inst, Turnstone Lp
- What technology area does this patent fall under?
- Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
- When was this patent published?
- Publication date Tue Sep 04 2018 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).